Assessment of transcription inhibition as a characteristic of immunogenic cell death.
Cell stress
Cellular imaging
Click chemistry
Dactinomycin
RNA synthesis
Journal
Methods in cell biology
ISSN: 0091-679X
Titre abrégé: Methods Cell Biol
Pays: United States
ID NLM: 0373334
Informations de publication
Date de publication:
2022
2022
Historique:
entrez:
5
9
2022
pubmed:
6
9
2022
medline:
9
9
2022
Statut:
ppublish
Résumé
Anticancer drugs that suppress DNA-to-RNA transcription are particularly efficient in stimulating immunogenic cell death and hence eradicate malignant cells in a way that they will ignite an antitumor immune response. This is therapeutically relevant as it allows treatment response to last beyond drug discontinuation. For this reason, it is important to measure transcription inhibition in a precise fashion. Here, we detail two complementary assays for the assessment of transcription inhibition, one that detects the physical separation of fibrillarin and nucleolin by two-color immunofluorescence and another that measures the diminution of incorporated 5-ethynyl uridine (EU) into RNA, as revealed by click chemistry and the per-cell-intensity of a fluorescent signal.
Identifiants
pubmed: 36064227
pii: S0091-679X(21)00131-X
doi: 10.1016/bs.mcb.2021.12.026
pii:
doi:
Substances chimiques
RNA
63231-63-0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
67-82Informations de copyright
Copyright © 2022 Elsevier Inc. All rights reserved.
Déclaration de conflit d'intérêts
Conflict of interest G.K. and O.K. are cofounders of Samsara Therapeutics. G.K. is a founder of everImmune and Therafast Bio.